To read the full story, subscribe or sign in.

Aimedbio’s ₩51B pre-IPO round to fuel new cancer ADCs

June 3, 2025

Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.

BioWorld Asia Financings Aging Cancer Toxicity/intoxication Antibody-drug conjugate

Today's news in brief

BioWorld

BioWorld briefs for Dec. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 9, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...